Stocktoria
Contineum Therapeutics, Inc. CTNM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-04-05
Contineum Therapeutics, Inc. statistics & valuation
Market cap$530.5M
P / B2.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | — | — | 32.2% |
| Net margin | — | — | 45.4% |
| FCF margin | — | — | 37.9% |
| Return on assets | -21.7% | -19.9% | 17.4% |
| Return on equity | -23.0% | -21.3% | -33.4% |
| Current ratio | 27.50 | 20.69 | 23.29 |
| Revenue growth | — | -100.0% | — |
Source: SEC EDGAR filings · CIK 0001855175 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.